| Detail | Information |
|---|---|
| Industry | Pharmaceuticals and Manufacturing |
| Location | India |
| Team Size | 2,459+ |
What MediagraphixPR Actually Did Here
An EU GMP certification is technical news on the surface. Underneath, it’s the single biggest credibility signal a pharma manufacturer can earn, proof that a facility meets standards good enough for the world’s most regulated markets. Our job was making sure that distinction didn’t get lost in translation between a compliance milestone and a business story.
◦ We reframed the certification as validation, not just a stamp. The press narrative positioned EU GMP as proof of Laborate’s readiness for regulated markets, not a routine box ticked. That single shift in framing is what separated this from every other “certification achieved” announcement in the pharma trade press.
◦ We took the story straight into the rooms where pharma decisions get made. Placements landed in The Economic Times Pharma, Express Pharma, Pharmabiz, Gene Online, and BioSpectrum, the exact outlets that pharma decision-makers, distributors, and potential partners actually read.
◦ We widened the net beyond the trade press alone. Coverage extended into mainstream and regional publications including Hari Bhoomi, Business News This Week, APN News, and Medical Dialogues, giving the story reach well past the pharma bubble.
◦ We let the industry carry the story further on its own. Express Pharma and Pharma Industrial India picked up the coverage and reshared it on LinkedIn, and that’s where organic traction among industry professionals actually kicked in, the kind of pickup a press release alone can’t manufacture.
◦ We anchored the entire narrative around the export opportunity. Every placement tied the certification back to what it actually unlocks: a strengthened export pipeline into Europe and the UK, directly aligned with Laborate’s five year vision of doubling international revenue.
What Laborate Pharmaceuticals Actually Does
Laborate Pharmaceuticals India Ltd stands as one of the country’s largest fully bootstrapped pharmaceutical companies, built on an extensive portfolio spanning generics, formulations, and healthcare solutions. Strong domestic distribution combined with a steadily growing international footprint has earned the company a reputation for quality driven, affordable medicines.
In July 2025, that reputation took a real step forward. Laborate’s oral solid dosage facility in Himachal Pradesh, at Paonta Sahib, earned EU Good Manufacturing Practices certification. That single approval put the European Union and the UK within reach, and gave Laborate a stronger footing to serve regulated markets while keeping its global supply chain moving.
The Challenge: Proving Global Readiness, Not Just Domestic Scale
A routine compliance update wasn’t going to cut it here. Laborate needed this milestone to do real work.
❯ Establish credibility as a globally compliant manufacturer, not just as a large domestic player with a long track record at home.
❯ Break through in both business and pharma trade media, so the story actually reached the decision-makers who matter for export partnerships.
❯ Position the certification as a strategic step toward scaling exports, not as a box-ticking regulatory formality that comes and goes without notice.
❯ Build momentum across both traditional press and digital platforms, so the story demonstrated trust and future readiness on every channel that mattered.
Press Release
Laborate Pharmaceuticals Secures EU-GMP Certification, Expands Global Supply Chain Capabilities
Key Points
- Laborate Pharmaceuticals secures EU-GMP certification for its Laborate Pharmaceuticals India Ltd, 111, Paonta Sahib (H.P.) facility
- Certification enables exports to European Union and other regulated markets
- Company in discussions with Europe and UK for co-development and commercial supply
- Facility equipped for manufacturing Oral Solid Dosage form (Tablet & Capsule) dosage forms in line with global standards
- Projected to increase international revenue by US $100 Million over the next 5 years
- Reinforces Laborate’s commitment to global quality, compliance, and expansion
New Delhi, 5th August 2025 – Laborate Pharmaceuticals, one of India’s prominent pharmaceutical manufacturing and exporting companies, recently announced that its manufacturing site in Laborate Pharmaceuticals India Ltd, 111, Paonta Sahib, (H.P.) has been granted the EU-GMP (European Union – Good Manufacturing Practice) certification from the relevant European regulatory agency.
The certification confirms compliance with the high standards set by the EU for pharmaceutical manufacturers and provides Laborate Pharmaceuticals with new opportunities to export and ship its products to the European Union and other regulated markets. The facility is built for Oral Solid Dosage Form, including Tablets & Capsules, and is fitted with state-of-the-art systems and processes to ensure consistent quality and regulatory compliance.
“This EU-GMP certification provides a clear pathway to our focus on world-class standards of quality and manufacturing to take an unprecedented step to be recognised as the EU-GMP accredited pharmaceutical organisation,” said Parag Bhatia, Director, Laborate Pharmaceuticals. “The certification confirms our capability to supply and export quality, safe and effective medicines to millions of people around the world.”
Laborate is currently negotiating advanced discussions with clients in Europe and UK for the co-development and supply of finished formulation products targeted to treat various therapeutic diseases. These agreements will play a key role in Laborate’s international strategy, pipeline expansion over the next 5 years.
The EU-GMP-certified facility, covering 157,500 square feet, has dedicated areas for 53000. The facility was audited and certified after a detailed investigation of its processes, systems, documentation, and quality management systems.
In fact, the facility certification provides a path to filing regulatory dossiers for multiple products in the EU market. The company intends to file 20 dossiers over the next 5 months to obtain approvals in Europe, UK, Australia and South Africa. The company is also exploring additional certifications via authorities such as GCC, EAEU to enhance its presence in regulated markets.
“We are focused on establishing longer-term partnerships with global companies that value reliable and scalable manufacturing at a cost-effective and compliant basis,” said Parag Bhatia, Director, Laborate Pharmaceuticals.
About Laborate Pharmaceuticals
Founded in 1985, Laborate Pharmaceuticals has grown into one of India’s largest pharma companies. A strong focus on affordability, accessibility, and compliance runs across multiple therapeutic segments and a wide portfolio of branded generics. The EU GMP certification marks a genuine turning point in its international growth strategy, opening the path to highly regulated global markets while the company continues serving India’s healthcare needs at home.
You Built The Product. Let’s Build The Recognition.
→ 150+ Brands, One Growth Partner